More reliable pain diagnosis tools needed in people with dementia

by Universitat Autònoma de Barcelona (UAB)

A study conducted by UAB and UNIZAR researchers concludes that a better pain assessment in patients with severe cognitive impairment is possible, using more reliable tools and spending more time with ...

Read more

EST64454: A Highly Soluble σ1 Receptor Antagonist Clinical Candidate for Pain Management

by Galchimia

Our latest article has just been published in the Journal of Medicinal Chemistry, describing some of the work carried out as part of our long-standing collaboration with Esteve ​Pharmaceuticals. The...

Read more

A new study considers methadone to be the most appropriate non-addictive opioid drug to treat chronic pain

by Universitat de Barcelona

​Administrating methadone instead of morphine is he most indicated pharmacological treatment in the fight against chronic pain, according to a new article published in the Jour​nal of Clinical Inv...

Read more

Anti-Aging Tips from a Chiropractor

by Life Length

People have been obsessed with staying young for almost all of recorded history. As the medical profession finds ways to keep people living longer, the problems with aging are becoming more obvious. B...

Read more

First photoactive drug for pain treatments

by Universitat de Barcelona

The new study published on the journal eLife has come up with the design of a “photo-drug” (JF-NP-26) with powerful therapeutic applications to treat pain, a molecule that can be specifically acti...

Read more

Esteve and Pompeu Fabra University strengthen their collaboration in research to combat pain

by UPF - Universitat Pompeu Fabra

Esteve and Pompeu Fabra University (UPF) strengthen their collaboration in the field of research to combat pain, a task promoted through the ESTEVE-UPF Joint Unit, located at the Barcelona Biomedical ...

Read more

Esteve, Mundipharma and Purdue announce a global partnership to drive innovation in pain management

by Parc Científic de Barcelona

The global pain market is valued at $37 bn. The neuropathic pain market is valued at $5.3 bn across US and EU5 with a Compound Annual Growth Rate (CAGR) of 8% over the past five years.

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

The important role of gastrointestinal m...

by Abyntek

​The gastrointestinal microbiota are all those groups of microorgani...

Photos Stream